Niacin dosing: Relationship to benefits and adverse effects
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Because of the original observation by Altschul et al., that nicotinic acid (niacin), not nicotinamide, in pharmacologic doses lowered human serum cholesterol levels, an avalanche of reports have been published over the past 45 years on the plasma lipid-regulating properties of this drug and its beneficial cardiovascular effects. A myriad of studies that have examined efficacy, safety, adverse effects, and pharmacologic properties of niacin rendered convincing evidence that niacin, used alone or combined with other agents, has favorable effects on serum lipoprotein regulation and on containment of atherothrombotic cardiovascular diseases. However, because of the unusual side effect profile of niacin and the availability of various formulations of this drug, niacin must be used prudently and with careful instruction and monitoring of patients. This review summarizes the pertinent and recent literature on niacin that impacts its therapeutic use. We also discuss some controversial issues and personal clinical experience and opinions on this topic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NA at pharmacological doses reduced serum cholesterol levels in humans; however, its use is limited due to the side effect causing skin flushing, accompanied by an unpleasant warmth sensation, and often itching [87].”
From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [87]
Citations
Cites
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824 · cited 1×
“Moreover, niacin has diminished cardiovascular endpoints as monotherapy in the Coronary Drug Project (CDP) [12] and in other combination drug trials (Table 1). Niacin therapy facilitated a 10.6% decline in all cause mortality in the 9year post-trial follow-up of the CDP [ 13 ].”
BackgroundInfluentialClofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Blankenhorn, D. H. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390230069027 · Cited by 1,655
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 845
Kane, J. P. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450230043027 · Cited by 829
Influence of nicotinic acid on serum cholesterol in man
Altschul, R., Hoffer, A., & Stephen, J. D. (1955) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(55)90070-9 · Cited by 724
Carlson, L. A., & ROSENHAMER, G. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15891.x · Cited by 677
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up
Cashin-Hemphill, L. (1990) · JAMA · doi:10.1001/jama.264.23.3013 · Cited by 493
Research works printed but not linked: 2
- Morgan JM, Capuzzi DM, Guyton JR, et al.: Treatment effect of niaspan, a controlled-release niacin, in patients with hypercholesterolemia:a placebo controlled trial. J Cardiovasc Pharmacol Therapeut 1996, 1:195–202. · DOI · Paper page
- Brusco OA, Capuzzi DM, Morgan, JM, et al.: Incidence of primary lipoprotein abnormalities and lipoprotein (a) excess in referred out-patients with premature CHD. CA J Invest Med 1995, 43 (Suppl 2):390A.
Cited by
Bieganowski, P., & Brenner, C. (2004) · Cell · doi:10.1016/s0092-8674(04)00416-7 · Cited by 750
NAD+ and Vitamin B3: From Metabolism to Therapies
Sauve, A. A. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120758 · Cited by 304
Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes
Cantó, C., Sauve, A. A., & Bai, P. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.004 · Cited by 246
“Niacin increases HDL cholesterol, better than any other known pharmacologic agent, and decreases LDL and VLDL cholesterol (Capuzzi et al., 2000).”
BackgroundNew Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney, J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.7.697 · Cited by 209
Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic “power station”
Trapani, L. (2012) · World Journal of Hepatology · doi:10.4254/wjh.v4.i6.184 · Cited by 177
Metadata
- Authors
- Capuzzi, D. M., Morgan, J. M., Brusco, O. A., & Intenzo, C. M.
- Affiliations
- Thomas Jefferson University (US)
- ORCID
- Intenzo, Charles M.
- Venue
- Current Atherosclerosis Reports
- Published
- 2000-12
- Volume
- 2
- Issue
- 1
- Pages
- 64-71
- ISSN
- 1523-3804 (ISSN-L)
- 1534-6242
- OpenAlex
- W1984146279
- Cited by
- 88
- References
- 39
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 3 · 2019: 4 · 2018: 2 · 2017: 1 · 2016: 5 · 2015: 3 · 2014: 3 · 2013: 4 · 2012: 5
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Current Atherosclerosis Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
- Keywords
- nicotinic acid, dosage, adverse effects, hypercholesterolemia, serum lipoproteins, cardiovascular disease prevention, atherothrombosis, drug safety, lipid-lowering therapy
- MeSH terms
- Anticholesteremic Agents, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Hypercholesterolemia, Niacin, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Niacin dosing: Relationship to benefits and adverse effects. https://app.cochat.ai/papers/10.1007/s11883-000-0096-y
- The paper
- Capuzzi, D. M., Morgan, J. M., Brusco, O. A., & Intenzo, C. M. (2000). Niacin dosing: Relationship to benefits and adverse effects. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-000-0096-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.